Azathioprine
- Generic Name
- Azathioprine
- Brand Names
- Azasan, Imuran, Jayempi
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7N7O2S
- CAS Number
- 446-86-6
- Unique Ingredient Identifier
- MRK240IY2L
- Background
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index. Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.
Azathiprine was granted FDA approval on 20 March 1968.
- Indication
Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.
- Associated Conditions
- Atopic Dermatitis, Crohn's Disease (CD), Immune Thrombocytopenia (ITP), Kidney Transplant Rejection, Lupus Nephritis, Multiple Sclerosis, Pericarditis, Psoriasis, Rheumatoid Arthritis, Uveitis
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
- Conditions
- Relapsing Polychondritis
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT06941376
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata
- Conditions
- Alopecia AreataAlopecia Areata(AA)
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Sheikh Zayed Medical College
- Target Recruit Count
- 60
- Registration Number
- NCT06786689
- Locations
- 🇵🇰
Sheikh Zayed Medical College/Hospital, Rahimyarkhan, Punjab, Pakistan
Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF
- Conditions
- Autoimmune Hepatitis
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 108
- Registration Number
- NCT06650124
Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial
- Conditions
- Chronic Actinic Dermatitis
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Pak Emirates Military Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT06476366
- Locations
- 🇵🇰
Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
Beneficial Effect of Silymarin in Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT06213857
- Locations
- 🇪🇬
Mabarra Hospital, Assiut, Egypt
🇪🇬Rajhy Hospital, Assiut, Egypt
Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05969730
- Locations
- 🇮🇷
Iran, Sari, Mazandaran, Iran, Islamic Republic of
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
- Conditions
- ANCA-associated VasculitisMaintenance Therapy
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT05965284
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
- Conditions
- NMO Spectrum DisorderAzathioprine Adverse Reaction
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 63
- Registration Number
- NCT05896605
- Locations
- 🇨🇳
Qingmeng Huang, Nanning, Guangxi, China
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
- Conditions
- Crohn DiseaseInfliximab
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 976
- Registration Number
- NCT05813860
Uterus Transplantation to Treat Infertility
- Conditions
- Uterine Factor Infertility
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 40
- Registration Number
- NCT05646992
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.